US Stocks Deer_Co, Docusign, Editas Medicine, Elbit Systems, Evogene, Faro Tech, Fate Therapeutics, Technical Analysis
Disruptive Innovation US Stocks: Deer & co [DE], Docusign inc [DOCU], Editas Medicine Inc [EDIT], Elbit Systems Ltd [ESLT], Evogene LTD [EVGN], Faro Technologies Inc [FARO] and Fate Therapeutics [FATE] Price Technical Analysis Elliott Wave and Trading Levels - tradinglounge.com
TRADING EDUCATION - ANALYSIS - TRADES - 20 DAY TRIAL
TradingLounge's 20 DAY TRIAL https://tradinglounge.com/
DEERE & CO [DE] (NYSE)
John Deere is the brand name of Deere & Company, an American corporation that manufactures agricultural, construction, and forestry machinery, diesel engines, drivetrains used in heavy equipment, and lawn care equipment.
DOCUSIGN INC [DOCU] (NASDAQ)
DocuSign, Inc. is an American company headquartered in San Francisco, California that allows organizations to manage electronic agreements. As part of the DocuSign Agreement Cloud, DocuSign offers eSignature, a way to sign electronically on different devices.
EDITAS MEDICINE INC [EDIT] (NASDAQ)
Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts, which aims to develop therapies based on CRISPR–Cas9 gene editing technology.
ELBIT SYSTEMS LTD [ESLT] (NASDAQ)
Elbit Systems Ltd. is an Israel-based international defense electronics company engaged in a wide range of programs throughout the world.
EVOGENE LTD [EVGN] (NASDAQ)
Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence
FARO TECHNOLOGIES INC [FARO] (NASDAQ)
FARO provides 3D solutions for as-built data capturing and 3D visualization of architecture, engineering and construction projects that allow AEC professionals to quickly and accurately extract desired 2D and 3D documentation and deliverables. Learn more.
FATE THERAPEUTICS [FATE] (NASDAQ)
Fate Therapeutics A clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. We are pioneering a revolutionary approach to cell therapy – we use renewable master induced pluripotent stem cell (iPSC) lines generated from our proprietary iPSC product platform to produce cellular immunotherapies that can be delivered off-the-shelf for the treatment of a large number of patients. We are also developing first-in-class allogeneic cell therapy product candidates utilizing healthy donor cells, which we modify ex vivo using pharmacologic modulators, such as small molecules, to improve the cells’ biological properties and therapeutic function.